Gemini Therapeutics closes $42.5M Series A for dry age-related macular degeneration therapy
Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A for the therapeutics business, which is focused on genetic causes for the condition.
Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A for the therapeutics business, which is focused on genetic causes for the condition.